Roger Brüggemann, PharmD, PhD

  Roger Brüggemann, PharmD, PhD

Roger JM Brüggemann, PharmD, PhD holds a position at the Department of Clinical Pharmacy at the Radboud University Medical Centre Nijmegen, the Netherlands (2007- ).

He obtained his M.Sc degree in pharmacy and a PharmD degree from Utrecht University, The Netherlands. He has been trained as a resident hospital pharmacist at The Hague Central Hospital Pharmacy. He then went on to receive his PhD from Radboud University Nijmegen Medical Centre on the topic of Clinical Pharmacology of azole antifungal drugs and the individualization of therapy. He received the price for best thesis of the Dutch Association of Clinical Pharmacology and Biopharmaceutics. 

Roger Brüggemann’s research interest area are in the management of invasive fungal infections, pharmacokinetics, pharmacodynamics and pharmacogenetics of antifungal agents in both humans and animals, therapeutic drug monitoring, drug-drug interactions and analytical analysis of antifungal drug in various matrices.

Additionally, he has experience in the design, conduct, analysis and reporting of single and multi-centre trials involving azole and echinocandin drugs in a wide variety of patients such as (pediatric) hematology and intensive care unit patients and healthy volunteers trials.

Roger is a member of a number of national and international societies including the “European Society for Clinical Microbiology and Infectious Diseases (ESCMID)”; the ESCMID PK/PD Study Group and the ESCMID Fungal Infections Study Group; the “International Society of Anti-Infective Pharmacology (ISAP); the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and the “Anti-infective Drugs Committee of the IATDMCT”; the Dutch Society for Hospital Pharmacist (NVZA) and the Special Interest Group for Infectious Diseases of the NVZA.

 In addition to his research, Roger works as a resident hospital pharmacist, is a consultant for the department of hematology, the intensive care and is a member of the regional Toxicology Expert Team. He is involved in routine patient TDM management.